OakChart

NRX Pharmaceuticals Inc

NRXPHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

2.44+0.08 (3.39%)
2026-11-12 04:16 CET
Market cap
106.50 USD m
Revenue, TTM
3.39 USD m
Net income, TTM
-23.48 USD m
Free cash flow, TTM
-20.67 USD m
EPS diluted, TTM
-0.74
P/E
-
Compare

Price

NRXP against its 20, 50 and 200-day averages
2050200miss
2.003.004.005.007.8M15.6MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26NRXPclose 2.4420-day 2.4850-day 2.87200-day 2.972.4452w high

51.7% under the 52-week high of 5.06 on 2 Jun 2026. 52-week low 1.62 on 9 Mar 2026. Last 15 sessions, 34.6% high to low

Volume 0.94× normal · the line is the 50-bar volume average

Profile

NRXP
52-week range, 24% of the way up
1.625.05

NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded by Jonathan C. Javitt on September 18, 2017 and is headquartered in Wilmington, DE.

Employees29
IPODec 04, 2017
Beta2.05
ATR, 14d0.20
Rel volume0.94
Short float27.13%
Insider own11.62%
Inst own28.22%

Snapshot

6 groups

Valuation

Index-
Market Cap106.50M
Enterprise Value81.06M
Income-23.48M
Sales3.39M
Book/sh-0.00
Cash/sh0.61
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees29
IPODec 04, 2017

Ratios

P/E-
Forward P/E-
PEG-
P/S31.42
P/B-
P/C3.99
P/FCF-
EV/EBITDA-
EV/Sales23.91
Quick Ratio0.86
Current Ratio0.86
Debt/Eq-
LT Debt/Eq-
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.74
EPS next Y-0.44
EPS next Q-0.21
EPS this Y35.07%
EPS next Y49.43%
EPS next 5Y-
EPS past 3/5Y39.52% 38.42%
Sales past 3/5Y- -
EPS Y/Y TTM67.07%
Sales Y/Y TTM-
EPS Q/Q55.24%
Sales Q/Q-
EarningsAug 17 BMO
EPS/Sales Surpr.-312.37% -17.20%

Ownership

Insider Own11.62%
Insider Trans0.00%
Inst Own28.22%
Inst Trans13.94%
ROA-120.42%
ROE-
ROIC-8209.79%
Gross Margin32.68%
Oper. Margin-588.13%
Profit Margin-691.81%
SMA20-1.75%
SMA50-14.98%
SMA200-17.93%
Trades-

Technical

Shs Outstand43.16M
Shs Float38.57M
Short Float27.13%
Short Ratio10.05
Short Interest10.46M
52W High5.05 -51.73%
52W Low1.62 50.62%
Volatility7.12% 9.19%
ATR (14)0.20
RSI (14)44.57
Beta2.05
Rel Volume0.94
Avg Volume1.04M
Volume980,158

Performance

Perf Week-2.01%
Perf Month-9.63%
Perf Quarter-26.95%
Perf Half Y-17.29%
Perf YTD-9.96%
Perf Year-2.01%
Perf 3Y-26.04%
Perf 5Y-96.21%
Perf 10Y-
Recom1.00
Target Price39.25
Prev Close2.36
Price2.44
Change %3.39%

Analyst ratings

latest 2 of 2
DateActionAnalystRating changeTargetImplied
Sep 08, 2025InitiatedHH.C. WainwrightBuy$40+1,539.3%
Apr 02, 2025InitiatedBBTIG ResearchBuy$18+637.7%

Peers

Mkt cap
TickerCompanyMkt cap
NMRANeumora Therapeutics Inc88.87M
GHRSGH Research PLC1.32B
ANROAlto Neuroscience Inc1.22B
AXSMAxsome Therapeutics Inc7.85B
TNXPTonix Pharmaceuticals Holding Corp75.20M
CMPSCompass Pathways Plc ADR1.32B
STIMNeuronetics Inc125.92M
LBRXLB Pharmaceuticals Inc1.45B
VTGNVistagen Therapeutics Inc8.34M
SUPNSupernus Inc6.12B

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
PSILAdvisorShares Psychedelics ETFAUM: 43.26M
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B

News

latest 14 of 100
  • NRx Pharmaceuticals Begins Selling U.S.-Made, Preservative-Free Ketamine Amid Long-Running Shortage (GlobeNewswire)
  • NRx Pharmaceuticals (Nasdaq:NRXP) Receives FDA Approval of Preservative-Free Ketamine Ahead of November 10 FDA Goal Date (GlobeNewswire) -14.66%
  • NRx Pharmaceuticals (Nasdaq: NRXP) to Host Conference Call on October 30, 2026 to Discuss Regulatory Milestone for Preservative-Free Ketamine (GlobeNewswire)
  • Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
  • NRx Pharmaceuticals (Nasdaq:NRXP) Announces Completion of Manufacturing Process Validation and Two-Year Stability of Preservative-Free Ketamine (GlobeNewswire)
  • NRx Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free Ketamine (GlobeNewswire)
  • NRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depression (GlobeNewswire)
  • NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine (GlobeNewswire)
  • GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS) (GlobeNewswire)
  • NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System (GlobeNewswire)
  • NRx Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • NRX Pharmaceuticals Inc (NRXP) (Q2 2026) Earnings Call Highlights: Advancing Ketamine Pipeline ... (GuruFocus.com)
  • Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
  • NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-17-0.440-0.107-0.4401.101.333
2026Q12026-05-15-0.0400.209-0.0441.0719.435
2025Q42026-03-23-0.0030.0070.0111.007.534
2025Q32025-11-17-0.270-0.020-0.2650.246.084
2025Q22025-08-18-0.980-0.150-0.9800.003.502
2025Q12025-05-15-0.340-0.283-0.3362.280.003
2024Q42025-03-17-0.728-0.367-0.7730.000.003
2024Q32024-11-14-0.150-0.555-0.1480.000.002
2024Q22024-08-14-0.750-0.695-0.7510.000.002
2024Q12024-05-14-0.740-0.550-0.7370.000.001
2023Q42024-03-28-0.500-0.700-0.5170.000.003
2023Q32023-11-13-0.700-1.100-0.7400.000.003
2023Q22023-08-14-1.200-1.333-1.1910.000.003
2023Q12023-05-16-1.600-1.350-1.6370.000.002
2022Q42023-03-30-1.500-1.450-1.5410.000.002
2022Q32022-11-14-1.400-1.400-1.3670.000.002

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2022FY-6.100-6.433-6.0450.000.00
2023FY-4.000-4.167-3.9810.000.00
2024FY-2.360-1.907-2.3610.000.00
2025FY-1.340-1.037-1.3401.2311.81
2026FY--0.870--5.61
2027FY--0.440--77.49
2028FY-0.030--517.6
2029FY-0.560--735.6
2030FY-0.990--947.8

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-11-073101.291.161.50
2026Q3S2026-10-313111.291.161.50
2026Q3S2026-10-303121.291.161.50
2026Q3S2026-09-293031.221.001.50
2026Q3S2026-08-262021.331.161.50
2026Q3S2026-08-243021.241.071.50
2026Q3S2026-08-173011.541.072.40
2026Q3S2026-08-103001.551.072.40
2026Q3S2026-08-023011.551.072.40
2026Q3S2026-08-014012.661.076.00
2026Q3S2026-07-084112.661.076.00
2026Q3S2026-06-184122.661.076.00
2026Q3S2026-05-273123.161.076.00
2026Q3S2026-05-2631112.771.0731.25

Estimate history

EPS, annual-0.1260.0740.803-15.108-74.361-6.045-3.981-2.361-1.337-0.7366
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.751-0.148-0.773-0.336-0.98-0.2650.011-0.044-0.439
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual000000001.2253.39
Period201720182019202020212022202320242025TTM
Sales, quarterly000000.2420.9831.0681.101
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.9040.9040.5154.2975.8816.6448.39214.59231.73443.158
Period201720182019202020212022202320242025MRQ
Shares, quarterly10.79211.37314.59217.1219.47427.68331.73433.47143.158
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue3.391.230.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A2.290.650.010.010.000.000.000.000.00
Gross Profit1.110.58-0.01-0.01-0.00-0.00-0.000.000.00
Selling, General and Administrative Excl. Other21.0716.7719.7027.5844.3395.2022.060.711.01
Research and Development5.413.786.2013.3717.0320.2610.62--
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-19.96-16.19-19.70-27.59-44.34-95.20-22.06-0.71-1.01
Interest Expense-0.671.080.12-0.020.06--
Unusual Expense7.7315.834.392.94-4.33-2.1629.66-0.00
Net Income Before Taxes-23.48-28.62-25.13-30.15-39.75-93.06-51.780.490.08
Income Taxes0.000.000.000.000.000.000.000.080.02
Consolidated Net Income-23.48-28.62-25.13-30.15-39.75-93.06-51.780.410.07
Net Income From Continuing Operations-23.48-28.62-25.13-30.15-39.75-93.06-51.780.410.07
Net Income-23.48-28.62-25.13-30.16-39.75-348.88-51.780.410.07
EPS (Recurring)-0.48-0.82-2.07-3.71-6.51-74.68-9.050.800.07
EPS (Basic, Before Extraordinaries)-0.74-1.34-2.36-3.98-6.04-74.36-15.110.800.07
EPS (Diluted)-0.74-1.34-2.36-3.98-6.04-74.36-15.110.800.07
EBITDA-19.49-16.05-19.70-27.58-44.33-95.20-22.06-0.71-
Non-Operating Income (Expense)5.364.070.040.490.250.000.001.211.09
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.390.180.490.393.637.790.73--
Price To Earnings Ratio-------198.691,393.44
Price To Sales Ratio45.3747.35-------
Gross Margin32.6847.10-------
Operating Margin-588.13-1,321.47-------
Net Margin-691.81-2,336.49-------
Shares Outstanding43.1631.7314.598.396.645.884.300.510.90
Market Capitalization106.50106.5026.6138.6075.08281.1165.5954.5992.16

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue1.101.070.980.240.000.000.000.00
Cost of Goods Sold Incl. D&A0.840.800.510.140.000.000.000.00
Gross Profit0.260.270.470.100.000.00-0.00-0.00
Selling, General and Administrative Excl. Other6.765.025.074.223.733.753.633.02
Research and Development2.121.310.561.430.990.801.040.61
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-6.50-4.75-4.59-4.12-3.73-3.75-3.63-3.02
Interest Expense0.240.230.67-----
Unusual Expense9.79-3.54-5.667.1413.851.775.45-1.39
Net Income Before Taxes-16.52-1.430.36-5.89-17.58-5.51-9.08-1.62
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-16.52-1.430.36-5.89-17.58-5.51-9.08-1.62
Net Income From Continuing Operations-16.52-1.430.36-5.89-17.58-5.51-9.08-1.62
Net Income-16.52-1.430.36-5.89-17.58-5.51-9.08-1.62
EPS (Recurring)-0.26-0.12-0.11-0.04-0.44-0.26-0.45-0.24
EPS (Basic, Before Extraordinaries)-0.44-0.040.01-0.26-0.98-0.34-0.77-0.15
EPS (Diluted)-0.44-0.040.01-0.26-0.98-0.34-0.77-0.15
EBITDA-6.33-4.58-4.49-4.08-3.73-3.75-3.63-3.02
Non-Operating Income (Expense)0.010.01-0.035.370.000.000.000.01
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.140.150.030.070.070.010.040.10
Price To Sales Ratio45.3730.0370.20303.15----
Gross Margin23.4325.4748.3242.98----
Operating Margin-590.46-444.57-467.34-1,701.65----
Net Margin-1,500.45-133.9036.62-2,433.88----
Shares Outstanding43.1633.4731.7327.6819.4717.1214.5911.37
Market Capitalization106.5070.4380.2378.4463.5834.6826.6118.17

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments7.801.444.5920.0527.611.866E-060.010.45
Short Term Receivables0.160.000.000.000.000.830.000.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets0.931.862.295.745.110.240.070.020.09
Total Current Assets8.893.306.8825.8032.712.930.070.030.54
Net Property, Plant & Equipment0.700.010.000.000.000.000.000.000.00
Total Investments and Advances0.400.000.000.000.000.0032.0170.7769.03
Intangible Assets2.72----0.000.000.000.00
Other Assets0.250.340.430.020.010.010.000.000.00
Total Assets12.963.657.3225.8232.732.9432.0770.8069.57
Short Term Debt Incl. Current Port. of LT Debt0.321.579.167.700.500.230.000.000.00
Accounts Payable4.270.004.632.083.693.150.000.000.00
Income Tax Payable------0.000.02-
Other Current Liabilities23.9920.305.255.817.7442.780.620.550.09
Total Current Liabilities28.5821.8619.0515.5911.9246.160.620.570.09
Long Term Debt0.325.010.002.820.000.551.950.690.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.000.000.000.00
Total Liabilities28.8926.8719.0518.4111.9246.712.571.260.09
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.0064.5464.47
Common Equity-15.94-23.22-11.747.4120.81-43.7729.505.005.00
Total Shareholders Equity-15.94-23.22-11.737.4120.81-43.7729.5069.5469.47
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity-15.94-23.22-11.737.4120.81-43.7729.5069.5469.47
Total Liabilities & Stockholders Equity12.963.657.3225.8232.732.9432.0770.8069.57
Book Value Per Share-0.50-1.59-1.401.123.54-10.1957.295.535.53
Tangible Book Value Per Share-0.59-1.59-1.401.123.54-10.1957.295.535.53
Full-Time Employees29----22--
Price to Book Ratio-619.29-1.33-6.214.4713.5123.691.8518.433,673.62
Return on Assets-344.70-458.25-182.00-135.81-479.96-295.740.790.09-
Return on Equity----281.79-789.51-2.690.820.10-
Return on Invested Capital----388.56-447.29-1.300.09-0.15
Quick Ratio0.310.150.361.662.740.060.110.055.76
Current Ratio0.310.150.361.662.740.060.110.055.76

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-23.48-28.62-25.13-30.15-39.75-93.06-51.780.410.07
Depreciation0.480.140.010.010.000.000.00--
Other Funds (Non Cash)4.4112.969.193.32-0.7060.2646.06-1.21-1.09
Funds from Operations-18.59-15.52-15.93-26.82-40.45-32.80-5.72-0.80-1.02
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-1.191.415.295.160.70-4.903.450.000.55
Income Taxes Payable------0.02-0.090.02
Cash from Operating Activities-19.77-14.11-10.64-21.66-39.76-37.70-2.27-0.79-0.47
Capital Expenditures-0.900.000.000.000.000.00-0.000.000.00
Net Assets From Acquisitions-2.38-2.380.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments-0.43-0.430.00-0.00-0.01-0.010.0040.25-0.69
Purchase of Investments-0.43-0.430.00-0.00-0.01-0.010.00-0.99-0.69
Sale Or Maturity of Investments0.000.000.000.000.000.000.0041.240.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.04
Cash from Investing Activities-3.71-2.810.00-0.00-0.01-0.01-0.0040.25-0.65
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock44.1415.865.919.2922.7153.682.63-40.73-0.01
Repurchase of Common Pref Stock0.000.000.000.000.000.000.00-40.730.00
Sale of Common Pref Stock44.1415.865.919.2922.7153.682.630.00-0.01
Proceedsfrom Stock Options34.676.394.881.1722.7127.360.050.00-0.01
Issuance or Reduction of Debt, Net3.127.421.57-3.099.50-0.180.621.260.69
Change in Long Term Debt3.097.741.25-3.0910.02-0.180.621.260.69
Issuance of Long Term Debt3.097.749.100.0010.020.000.621.330.69
Reduction of Long Term Debt0.000.00-7.85-3.090.00-0.180.00-0.070.00
Net Financing Active Other Cash Flow0.000.000.000.000.009.950.000.000.00
Other Financing Activities Uses0.000.000.000.000.00-1.100.000.000.00
Cash from Financing Activities47.2623.287.496.2032.2163.463.25-39.460.68
Net Change in Cash23.786.35-3.15-15.46-7.5525.750.98-0.01-0.44
Free Cash Flow-20.67-14.11-10.64-21.66-39.76-37.70-2.27-0.79-0.47
Preferred Dividends (Cash Flow)-0.000.00-0.00-0.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments26.696.717.807.182.915.55
Short Term Receivables0.210.180.163.330.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets2.270.470.931.441.681.71
Total Current Assets29.167.368.8911.954.597.26
Net Property, Plant & Equipment1.751.200.700.420.010.01
Total Investments and Advances0.400.400.400.000.000.00
Intangible Assets2.622.672.722.39--
Other Assets0.220.280.250.240.240.33
Total Assets34.1611.9012.9615.004.847.59
Short Term Debt Incl. Current Port. of LT Debt0.790.390.3210.2510.238.40
Accounts Payable3.154.404.274.263.630.00
Other Current Liabilities29.9420.3923.9926.0926.5924.35
Total Current Liabilities33.8725.1828.5840.5940.4532.75
Long Term Debt0.460.540.320.160.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities34.3325.7228.8940.7540.4532.75
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-0.17-13.82-15.94-25.75-35.62-25.16
Total Shareholders Equity-0.17-13.82-15.94-25.75-35.62-25.16
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-0.17-13.82-15.94-25.75-35.62-25.16
Total Liabilities & Stockholders Equity34.1611.9012.9615.004.847.59
Book Value Per Share-0.00-0.41-0.50-0.93-1.83-1.47
Tangible Book Value Per Share-0.06-0.49-0.59-1.02-1.83-1.47
Full-Time Employees--29---
Price to Book Ratio-619.29-4.24-2.91-1.80-2.22-1.29
Return on Assets-120.42-251.79-344.71-391.21-669.06-423.80
Return on Invested Capital-5,776.22-----
Quick Ratio0.860.290.310.290.110.22
Current Ratio0.860.290.310.290.110.22

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-16.52-1.430.36-5.89-17.58-5.51
Depreciation0.170.170.100.040.000.00
Other Funds (Non Cash)10.92-3.36-5.532.3914.072.03
Funds from Operations-5.43-4.63-5.07-3.46-3.51-3.48
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-3.440.331.360.57-0.520.00
Cash from Operating Activities-8.88-4.29-3.71-2.89-4.03-3.48
Capital Expenditures-0.900.000.000.000.000.00
Net Assets From Acquisitions0.000.000.18-2.560.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.21-0.21-0.430.000.000.00
Purchase of Investments0.21-0.21-0.430.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.68-0.21-0.25-2.560.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock29.123.421.649.951.013.25
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock29.123.421.649.951.013.25
Proceedsfrom Stock Options29.123.42-7.839.951.013.25
Issuance or Reduction of Debt, Net0.410.002.93-0.230.384.33
Change in Long Term Debt0.000.003.090.000.004.65
Issuance of Long Term Debt0.000.003.090.000.004.65
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities29.533.424.589.731.397.58
Net Change in Cash19.97-1.080.614.27-2.644.11
Free Cash Flow-9.77-4.29-3.71-2.89-4.03-3.48

Revenue breakdown

Procedures2025: 371.00K
Therapy2025: 854.00K
United States2025: 1.23M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3027.13%10.5M38.6M1.10M
2026-10-1526.01%9.9M38.3M846.52K
2026-09-3025.60%9.8M38.3M888.83K
2026-09-1525.55%9.8M38.3M941.50K
2026-08-3124.30%9.3M38.3M1.13M
2026-08-1422.67%8.7M38.3M1.28M
2026-07-3117.68%6.6M37.1M1.20M
2026-07-1516.72%6.2M37.1M1.30M
2026-06-3014.56%5.4M37.1M1.26M
2026-06-1515.40%5.7M37.1M1.28M
2026-05-2915.54%5.0M32.0M1.08M
2026-05-1514.59%4.7M32.0M931.57K
2026-04-3015.08%4.4M29.2M826.68K
2026-04-1511.12%3.2M29.2M713.44K
2026-03-318.59%2.5M29.3M1.07M
2026-03-139.75%2.7M28.2M964.81K
2026-02-278.73%2.5M28.2M943.59K
2026-02-139.53%2.7M28.2M922.16K
2026-01-3010.63%2.8M26.2M924.30K
2026-01-1513.48%3.5M26.2M865.12K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.501.452.450.000.0000.000.000.0000.0000.000
call1.000.951.950.0012.4890.000.000.923-0.0380.001
call1.500.351.350.008.0170.000.000.844-0.0410.001
call2.000.051.050.006.1240.000.000.743-0.0360.001
call2.500.000.250.121.8191722.000.546-0.0200.002
call5.000.000.050.053.1012,5873.000.107-0.0120.001
call7.500.001.000.054.1465.000.000.087-0.0130.001
put0.500.001.000.0020.1440.000.00-0.017-0.0170.000
put1.000.001.000.009.9350.000.00-0.090-0.0320.001
put1.500.001.000.006.3540.000.00-0.169-0.0320.001
put2.000.001.000.004.0310.000.00-0.280-0.0270.001
put2.500.000.500.402.06867.000.00-0.503-0.0160.002
put5.002.103.102.207.05051.000.00-0.893-0.0120.001
put7.504.605.600.007.8170.000.00-0.914-0.0140.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-05DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-11-05DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-12-17SEC
2026-11-044Statement of changes in beneficial ownership of securities2026-07-28SEC
2026-11-044Statement of changes in beneficial ownership of securities2026-07-28SEC
2026-11-028-KCurrent report2026-10-30SEC
2026-10-168-KCurrent report2026-10-16SEC
2026-10-058-KCurrent report2026-09-29SEC
2026-09-168-KCurrent report2026-09-15SEC
2026-09-148-KCurrent report2026-09-08SEC
2026-08-178-KCurrent report2026-08-17SEC
2026-08-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-078-KCurrent report2026-08-07SEC
2026-07-228-KCurrent report2026-07-21SEC
2026-06-048-KCurrent report2026-06-03SEC
2026-06-03424B5SEC
2026-06-028-KCurrent report2026-06-02SEC
2026-06-02424B5SEC
2026-05-2225-NSESEC
2026-05-1510-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-15SCHEDULE 13G/ASEC
2026-03-248-KCurrent report2026-03-23SEC
2026-03-2310-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-02-24DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-02-23ARSAnnual report to security holders. 2024-12-31SEC
2026-02-23DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-03-23SEC
2026-02-174Statement of changes in beneficial ownership of securities2026-01-27SEC
2026-02-173Initial statement of beneficial ownership of securities2026-01-27SEC
2026-02-178-KCurrent report2026-02-17SEC
2026-02-178-KCurrent report2026-02-17SEC
2026-02-17424B5SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
B Group, Inc.9.76%
VANGUARD CAPITAL MANAGEMENT LLC3.86%
AMERIPRISE FINANCIAL INC2.21%
BALYASNY ASSET MANAGEMENT L.P.2.13%
AdvisorShares Investments LLC1.86%
CITADEL ADVISORS LLC1.62%
COMMONWEALTH EQUITY SERVICES, LLC1.36%
GEODE CAPITAL MANAGEMENT, LLC1.03%
UBS Group AG0.88%
BlackRock, Inc.0.53%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND3.02%
AdvisorShares Psychedelics ETF1.57%
VANGUARD EXTENDED MARKET INDEX FUND0.69%
Fidelity Extended Market Index Fund0.33%
iShares Micro-Cap ETF0.25%
Fidelity Total Market Index Fund0.12%
Fidelity Series Total Market Index Fund0.10%
VANGUARD BALANCED INDEX FUND0.05%
Fidelity Nasdaq Composite Index Fund0.05%
VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND0.04%

OakChart. NRXP. Cached 15 minutes.

Some panels did not load: insider.